flutiform 125 µg - 5 µg press. inhal. susp. press. cont.
mundipharma bv-srl - fluticasone propionate 0,125 mg; sodium cromoglicate 0,024 mg; formoterol fumarate dihydrate 0,005 mg - pressurised inhalation, suspension - 125 µg - 5 µg - fluticasone propionate 125 µg; formoterol fumarate dihydrate 5 µg - formoterol and fluticasone
flutiform k-haler 125 µg/dose - 5 µg/dose press. inhal. susp. inhaler
mundipharma bv-srl - fluticasone propionate 0,125 mg/dose; formoterol fumarate dihydrate 0,005 mg/dose - pressurised inhalation, suspension - 125 µg/dose - 5 µg/dose - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - formoterol and fluticasone
pms-fluticasone hfa metered-dose aerosol
pharmascience inc - fluticasone propionate - metered-dose aerosol - 50mcg - fluticasone propionate 50mcg - adrenals
pms-fluticasone hfa metered-dose aerosol
pharmascience inc - fluticasone propionate - metered-dose aerosol - 250mcg - fluticasone propionate 250mcg - adrenals
pms-fluticasone powder
pharmascience inc - fluticasone propionate - powder - 100mcg - fluticasone propionate 100mcg - adrenals
pms-fluticasone powder
pharmascience inc - fluticasone propionate - powder - 250mcg - fluticasone propionate 250mcg - adrenals
pms-fluticasone powder
pharmascience inc - fluticasone propionate - powder - 500mcg - fluticasone propionate 500mcg - adrenals
seretide
glaxosmithkline nz limited - fluticasone propionate 20mg equivalent to 125 µg/dose; ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol; - aerosol inhaler, metered dose - 125µg/25µg - active: fluticasone propionate 20mg equivalent to 125 µg/dose salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.
fluticasone cipla inhaler fluticasone propionate 250 microgram/actuation inhalation pressurised aerosol can metered dose
cipla australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.
fluticasone cipla inhaler fluticasone propionate 125 microgram/actuation inhalation pressurised aerosol can metered dose
cipla australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.